Sculati Wealth Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Sculati Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% during the third quarter, HoldingsChannel reports. The firm owned 2,047 shares of the biopharmaceutical company’s stock after buying an additional 38 shares during the period. Sculati Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,970,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of REGN. Mizuho Securities USA LLC increased its position in shares of Regeneron Pharmaceuticals by 625.5% during the 3rd quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company’s stock valued at $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Tri Locum Partners LP boosted its stake in Regeneron Pharmaceuticals by 104.5% in the second quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock worth $18,410,000 after buying an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 50.8% during the third quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company’s stock valued at $10,082,000 after acquiring an additional 3,231 shares during the last quarter. Catalytic Wealth RIA LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $1,334,000. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 12.3% in the 3rd quarter. Daiwa Securities Group Inc. now owns 20,384 shares of the biopharmaceutical company’s stock valued at $21,428,000 after purchasing an additional 2,234 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Bank of America reissued an “underperform” rating and issued a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Citigroup initiated coverage on Regeneron Pharmaceuticals in a research report on Thursday, November 14th. They set a “neutral” rating and a $895.00 price target on the stock. Barclays lowered their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Finally, Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.90.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $773.00 on Thursday. The company has a 50-day simple moving average of $860.87 and a two-hundred day simple moving average of $1,007.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The firm has a market capitalization of $84.94 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.